![](https://i0.wp.com/psinvestor.com/wp-content/uploads/2018/07/horse-race-dubai.jpg?resize=678%2C381&ssl=1)
Uncategorized
Galectin Blocker is Front Runner in Fight Against NASH-Cirrhosis
GALT’s upcoming phase 3 trial patient population will be without varices and includes an interim analysis. An interim analysis creates the opportunity for GALT to submit a New Drug Application (NDA) at the 18 month mark […]